# 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

> **NCT06689085** · PHASE3 · RECRUITING · sponsor: **Halozyme Therapeutics** · enrollment: 100 (estimated)

## Conditions studied

- Hypogonadism, Male

## Interventions

- **COMBINATION_PRODUCT:** Testosterone enanthate

## Key facts

- **NCT ID:** NCT06689085
- **Lead sponsor:** Halozyme Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-07
- **Primary completion:** 2028-03
- **Final completion:** 2030-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06689085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06689085, "52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06689085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*